-
公开(公告)号：US12121745B2
公开(公告)日：2024-10-22
申请号：US17640608
申请日：2020-08-12
申请人： UNIVERSITÄTSMEDIZIN GREIFSWALD , CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN , TECHNISCHE UNIVERSITÄT BERLIN , FERDINAND-BRAUN-INSTITUT GGMBH, LEIBNIZ-INSTITUT FÜR HÖCHSTFREQUENZTECHNIK
发明人： Martina Meinke , Jürgen Lademann , Axel Kramer , Michael Kneissl , Tim Wernicke , Ulrike Winterwerber , Sven Einfeldt
IPC分类号： A61N5/06
CPC分类号： A61N5/0624 , A61N2005/063 , A61N2005/0652 , A61N2005/0661 , A61N2005/0666
摘要： The invention relates to a device and a method for UV antisepsis, in particular for intracorporeal in vivo UV antisepsis on the human and animal body in the event of colonization with multiresistant pathogens (MRPs) such as methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE). The device comprises a light emitting diode chip, LED chip, configured to emit radiation in the UVC spectral range, wherein the LED chip forms a light emitting diode, LED, with a package; a spectral filter element set up to limit the radiation emitted by the LED chip substantially to wavelengths below 235 nm; and an optical element for directional emission of the radiation emitted by the LED.
-
公开(公告)号：US20240189352A1
公开(公告)日：2024-06-13
申请号：US18286933
申请日：2022-04-14
申请人： MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN in der Helmholtz-Gemeinschaft , Charité - Universitätsmedizin Berlin
IPC分类号： A61K35/17 , C07K14/725 , C12N15/86
CPC分类号： A61K35/17 , C07K14/7051 , C12N15/86 , C12N2740/10041
摘要： The invention is based on antigen binding proteins (ABPs) such as T-cell receptors (TCR) expressed on T-cells, which have a specificity to bind to MIC presented Rac2 and Rac1 derived neo-epitopes. Hence, such MHC presented peptides are derived from mutated versions of Rac1 and Rac2, such as preferably RAC2P29L and/or RAC1P29S. Provided are isolated ABPs as well as genetic constructs expressing the ABPs, recombinant host cells harboring the ABP of the invention and methods for producing such ABPs and host cells. Moreover, provided are medical applications involving the TCR of the invention, for example in context of an adoptive T-cell therapy.
-
公开(公告)号：US20240025849A1
公开(公告)日：2024-01-25
申请号：US18023233
申请日：2021-08-26
申请人： MAX DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT , CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人： Helmut KETTENMANN , Susanne WOLF , Philipp JORDAN , Sabrina KLEISSLE , Martin NEUENSCHWANDER , Edgar SPECKER , Marc NAZARE
IPC分类号： C07D207/16 , A61K47/54 , A61K47/60 , C07D471/04 , C07D405/06 , C07D409/06 , C07D403/06 , C07D405/12 , C07D401/06 , C07D403/12 , C07D205/04 , C07D417/12 , C07D209/42 , C07D217/26 , C07D409/12 , C07D211/60 , A61P9/10 , A61P25/28
CPC分类号： C07D207/16 , A61K47/545 , A61K47/60 , C07D471/04 , C07D405/06 , C07D409/06 , C07D403/06 , C07D405/12 , C07D401/06 , C07D403/12 , C07D205/04 , C07D417/12 , C07D209/42 , C07D217/26 , C07D409/12 , C07D211/60 , A61P9/10 , A61P25/28
摘要： The invention relates to compounds useful as inhibitors of NO production, especially inhibitors of the inducible NO synthase iNOS expressed by microglia and macrophages. The invention also relates to pharmaceutical compositions comprising these compounds and to therapeutic uses of these compounds, especially in the prophylaxis or treatment of conditions characterized by excess NO production, such as ischemic stroke and retinopathies.
-
4.发明公开公开(公告)号：US20230270872A1
公开(公告)日：2023-08-31
申请号：US18012710
申请日：2020-07-09
发明人： Ruben POSTEL , Guy HERMANS , Hendrik FUCHS
CPC分类号： A61K47/6807 , A61K45/06 , A61K47/6855 , A61K47/6849 , A61P35/00
摘要： The invention relates to a conjugate for transferring a saponin of the monodesmosidic triterpene glycoside type or of the bidesmosidic triterpene glycoside type from outside a cell into said cell, the conjugate comprising a single-domain antibody, capable of binding to said cell, covalently bound to a saponin. The invention also relates to a pharmaceutical combination comprising a first pharmaceutical composition comprising the conjugate of the invention and a second pharmaceutical composition comprising an active pharmaceutical ingredient, or to a pharmaceutical composition comprising the conjugate of the invention and an active pharmaceutical ingredient. In addition, the invention relates to the pharmaceutical combination of the invention or the pharmaceutical composition of the invention, for use as a medicament, or for use in the treatment or the prophylaxis of a cancer, an auto-immune disease, an infection, an enzyme deficiency, a gene defect. Furthermore, the invention relates to an in vitro or ex vivo method for transferring a molecule from outside a cell to inside said cell, comprising the application of the conjugate of the invention. Finally, the invention relates to a kit of parts, comprising the pharmaceutical combination of the invention or the pharmaceutical composition of the invention, or the conjugate of the invention, and instructions for use thereof.
-
公开(公告)号：US20230242911A1
公开(公告)日：2023-08-03
申请号：US18004877
申请日：2021-07-09
IPC分类号： C12N15/113 , A61P9/00 , C12N5/077
CPC分类号： C12N15/113 , A61P9/00 , C12N5/0657 , C12N2310/141 , C12N2310/113 , C12N2506/45
摘要： The invention is directed to a miRNA with a RNA sequence comprising or consisting of hsa-miR-515-3p with SEQ ID NO: 1, and hsa-miR-519e-3p with SEQ ID NO:2, or a member of the miR-517 family, specifically hsa-miR-517c-3p, hsa-miR-517a-3p, or a primary transcript thereof, a precursor thereof, a mimic thereof or a combination for use as a medicament, preferably for use in treatment of a cardiac disease associated with loss of cardiac myocytes.
-
公开(公告)号：US20220339467A1
公开(公告)日：2022-10-27
申请号：US17640608
申请日：2020-08-12
申请人： UNIVERSITÄTSMEDIZIN GREIFSWALD , CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN , TECHNISCHE UNIVERSITÄT BERLIN , FERDINAND-BRAUN-INSTITUT GGMBH, LEIBNIZ-INSTITUT FÜRHÖCHSTFREQUENZTECHNIK
发明人： Martina MEINKE , Jürgen LADEMANN , Axel KRAMER , Michael KNEISSL , Tim WERNICKE , Ulrike WINTERWERBER , Sven EINFELDT
IPC分类号： A61N5/06
摘要： The invention relates to a device and a method for UV antisepsis, in particular for intracorporeal in vivo UV antisepsis on the human and animal body in the event of colonization with multiresistant pathogens (MRPs) such as methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE). The device comprises a light emitting diode chip, LED chip, configured to emit radiation in the UVC spectral range, wherein the LED chip forms a light emitting diode, LED, with a package; a spectral filter element set up to limit the radiation emitted by the LED chip substantially to wavelengths below 235 nm; and an optical element for directional emission of the radiation emitted by the LED.
-
公开(公告)号：US20220162705A1
公开(公告)日：2022-05-26
申请号：US17297944
申请日：2019-11-29
发明人： Carsten DENKERT , Bruno SINN , Sibylle LOIBL , Karsten WEBER , Thomas KARN
IPC分类号： C12Q1/6886
摘要： The present invention relates to methods, kits, systems and uses thereof for prediction of the response or resistance to and/or benefit from a cancer immunotherapy of a subject suffering from or being at risk of developing a neoplastic disease, in particular breast cancer, based on the measurement(s) of expression level(s) of at least one marker in samples of said subject. Equally, the present invention relates to methods, kits, systems and uses thereof for predicting the outcome from the cancer immunotherapy treatment in said subject based on the measurement(s) of the expression level(s) of the at least one marker in samples of said subject. Further, the present invention relates to the cancer immunotherapy for use in the treatment of the neoplastic disease, in particular breast cancer, in the subject and to methods for cancer immunotherapy treatment by using the cancer immunotherapy according to the methods of the present invention.
-
公开(公告)号：US20220003748A1
公开(公告)日：2022-01-06
申请号：US17298618
申请日：2019-12-19
摘要： The present invention relates to a method for preserving urinary cells, the method comprising the step of contacting a urine sample obtained from a patient with a buffer substance suitable to create and/or maintain a pH value in the range of 6 to 8, particularly approx. 7, within said urine sample, and a formaldehyde releasing compound.
-
公开(公告)号：US11161887B2
公开(公告)日：2021-11-02
申请号：US16488601
申请日：2018-02-27
发明人： Jakob Völkl , Ioana Alesutan , Jürgen Scherberich
摘要： Described herein is the use of a uromodulin polypeptide in prevention or therapy of vascular calcification or a disease caused by, or related to, vascular calcification, particularly vascular calcification in chronic kidney disease, in diabetes, in aging and in atherosclerosis.
-
公开(公告)号：US20210190797A1
公开(公告)日：2021-06-24
申请号：US17180616
申请日：2021-02-19
发明人： Claudia MESSING , Katja Steinhagen , Erik Lattwein , Konstanze Stiba , Fabian Lindhorst , Eva Neugebauer , Marcel Müller , Victor Corman
IPC分类号： G01N33/68 , G01N33/543
摘要： A method diagnoses a SARS-CoV-2 infection and includes detecting the presence or absence of an antibody to SEQ ID NO: 1, preferably IgA class antibody, in a sample from a subject. A method differentially diagnoses a coronavirus infection. An antibody to SEQ ID NO: 1, preferably IgA class antibody, is used for diagnosing a SARS-CoV-2 infection or for the differential diagnosis of a coronavirus infection, preferably for distinguishing between a SARS-CoV-2, MERS and NL63, 229E, OC43 and HKU1 infection. A kit includes a polypeptide comprising SEQ ID NO: 1 or a variant thereof, preferably coated to a diagnostically useful carrier and one or more of the following reagents: an antibody to SEQ ID NO: 1, a washing buffer, a means for detecting the presence of an antibody, preferably IgA class antibody, preferably a secondary antibody binding specifically to IgA class antibodies, preferably comprising a detectable label, and a dilution buffer.
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.048 秒)
